A focus on valproate and cognitive deficits in Bipolar Disorders: A mini-review

A. Pigoni, G. M. Mandolini, G. Delvecchio, C. Bressi, J. C. Soares, P. Brambilla

Research output: Contribution to journalArticle

Abstract

Background: : Cognitive deficits represent a core feature of Bipolar Disorder (BD), which seem to characterize this disorder regardless of the mood phase. However, the role of pharmacological treatment in determining cognitive alterations is still not clear. Indeed, although drugs improve cognition by targeting mood symptoms, they could also carry their own cognitive side effects. This is true especially for mood stabilizers as they are the most commonly prescribed drugs in patients affected by BD and they are usually administered also during euthymic phases. Methods: : In this context, the present review aimed at summarizing the results of the studies evaluating the impact of valproate on cognitive functions in patients suffering from BD, as primary or secondary results. The inclusion criteria were met by ten studies. Specifically, we included one double-blind quasi-randomized study and nine cross-sectional or naturalistic studies, which a) used healthy subjects as control group (N = 1), b) compared valproate treated patients with healthy individuals and other treatments (N = 5), and c) compared valproate treated patients just with other treatments, with a specific focus on lithium (N = 3). Results: : Overall the results suggested a negative effect of valproate on cognitive functions in chronically-treated patients affected by BD. Notably, it has been found that the working memory was the most affected cognitive domain. Limitations: : Few studies directly explored the effect of valproate on cognition in BD. Conclusions: : These findings seem to suggest that valproate might have a negative effect on cognitive functions, especially on working memory domain. However, the results should be taken cautiously since the limited number of available studies published so far. In conclusion, these evidences seem to point out that the possible cognitive side effects of pharmacological treatments should be carefully taken into account, especially in chronic patients.

Original languageEnglish
Pages (from-to)277-281
JournalJournal of Affective Disorders
Volume261
DOIs
Publication statusPublished - 2020

Fingerprint

Valproic Acid
Bipolar Disorder
Cognition
Short-Term Memory
Pharmacology
Therapeutics
Mood Disorders
Lithium
Pharmaceutical Preparations
Healthy Volunteers
Cross-Sectional Studies
Control Groups

Keywords

  • Adverse events
  • Bipolar disorder
  • Cognition
  • Treatment
  • Valproate

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

A focus on valproate and cognitive deficits in Bipolar Disorders : A mini-review. / Pigoni, A.; Mandolini, G. M.; Delvecchio, G.; Bressi, C.; Soares, J. C.; Brambilla, P.

In: Journal of Affective Disorders, Vol. 261, 2020, p. 277-281.

Research output: Contribution to journalArticle

Pigoni, A. ; Mandolini, G. M. ; Delvecchio, G. ; Bressi, C. ; Soares, J. C. ; Brambilla, P. / A focus on valproate and cognitive deficits in Bipolar Disorders : A mini-review. In: Journal of Affective Disorders. 2020 ; Vol. 261. pp. 277-281.
@article{1e8acea17d5741f485caa3d35a56509e,
title = "A focus on valproate and cognitive deficits in Bipolar Disorders: A mini-review",
abstract = "Background: : Cognitive deficits represent a core feature of Bipolar Disorder (BD), which seem to characterize this disorder regardless of the mood phase. However, the role of pharmacological treatment in determining cognitive alterations is still not clear. Indeed, although drugs improve cognition by targeting mood symptoms, they could also carry their own cognitive side effects. This is true especially for mood stabilizers as they are the most commonly prescribed drugs in patients affected by BD and they are usually administered also during euthymic phases. Methods: : In this context, the present review aimed at summarizing the results of the studies evaluating the impact of valproate on cognitive functions in patients suffering from BD, as primary or secondary results. The inclusion criteria were met by ten studies. Specifically, we included one double-blind quasi-randomized study and nine cross-sectional or naturalistic studies, which a) used healthy subjects as control group (N = 1), b) compared valproate treated patients with healthy individuals and other treatments (N = 5), and c) compared valproate treated patients just with other treatments, with a specific focus on lithium (N = 3). Results: : Overall the results suggested a negative effect of valproate on cognitive functions in chronically-treated patients affected by BD. Notably, it has been found that the working memory was the most affected cognitive domain. Limitations: : Few studies directly explored the effect of valproate on cognition in BD. Conclusions: : These findings seem to suggest that valproate might have a negative effect on cognitive functions, especially on working memory domain. However, the results should be taken cautiously since the limited number of available studies published so far. In conclusion, these evidences seem to point out that the possible cognitive side effects of pharmacological treatments should be carefully taken into account, especially in chronic patients.",
keywords = "Adverse events, Bipolar disorder, Cognition, Treatment, Valproate",
author = "A. Pigoni and Mandolini, {G. M.} and G. Delvecchio and C. Bressi and Soares, {J. C.} and P. Brambilla",
year = "2020",
doi = "10.1016/j.jad.2019.08.008",
language = "English",
volume = "261",
pages = "277--281",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - A focus on valproate and cognitive deficits in Bipolar Disorders

T2 - A mini-review

AU - Pigoni, A.

AU - Mandolini, G. M.

AU - Delvecchio, G.

AU - Bressi, C.

AU - Soares, J. C.

AU - Brambilla, P.

PY - 2020

Y1 - 2020

N2 - Background: : Cognitive deficits represent a core feature of Bipolar Disorder (BD), which seem to characterize this disorder regardless of the mood phase. However, the role of pharmacological treatment in determining cognitive alterations is still not clear. Indeed, although drugs improve cognition by targeting mood symptoms, they could also carry their own cognitive side effects. This is true especially for mood stabilizers as they are the most commonly prescribed drugs in patients affected by BD and they are usually administered also during euthymic phases. Methods: : In this context, the present review aimed at summarizing the results of the studies evaluating the impact of valproate on cognitive functions in patients suffering from BD, as primary or secondary results. The inclusion criteria were met by ten studies. Specifically, we included one double-blind quasi-randomized study and nine cross-sectional or naturalistic studies, which a) used healthy subjects as control group (N = 1), b) compared valproate treated patients with healthy individuals and other treatments (N = 5), and c) compared valproate treated patients just with other treatments, with a specific focus on lithium (N = 3). Results: : Overall the results suggested a negative effect of valproate on cognitive functions in chronically-treated patients affected by BD. Notably, it has been found that the working memory was the most affected cognitive domain. Limitations: : Few studies directly explored the effect of valproate on cognition in BD. Conclusions: : These findings seem to suggest that valproate might have a negative effect on cognitive functions, especially on working memory domain. However, the results should be taken cautiously since the limited number of available studies published so far. In conclusion, these evidences seem to point out that the possible cognitive side effects of pharmacological treatments should be carefully taken into account, especially in chronic patients.

AB - Background: : Cognitive deficits represent a core feature of Bipolar Disorder (BD), which seem to characterize this disorder regardless of the mood phase. However, the role of pharmacological treatment in determining cognitive alterations is still not clear. Indeed, although drugs improve cognition by targeting mood symptoms, they could also carry their own cognitive side effects. This is true especially for mood stabilizers as they are the most commonly prescribed drugs in patients affected by BD and they are usually administered also during euthymic phases. Methods: : In this context, the present review aimed at summarizing the results of the studies evaluating the impact of valproate on cognitive functions in patients suffering from BD, as primary or secondary results. The inclusion criteria were met by ten studies. Specifically, we included one double-blind quasi-randomized study and nine cross-sectional or naturalistic studies, which a) used healthy subjects as control group (N = 1), b) compared valproate treated patients with healthy individuals and other treatments (N = 5), and c) compared valproate treated patients just with other treatments, with a specific focus on lithium (N = 3). Results: : Overall the results suggested a negative effect of valproate on cognitive functions in chronically-treated patients affected by BD. Notably, it has been found that the working memory was the most affected cognitive domain. Limitations: : Few studies directly explored the effect of valproate on cognition in BD. Conclusions: : These findings seem to suggest that valproate might have a negative effect on cognitive functions, especially on working memory domain. However, the results should be taken cautiously since the limited number of available studies published so far. In conclusion, these evidences seem to point out that the possible cognitive side effects of pharmacological treatments should be carefully taken into account, especially in chronic patients.

KW - Adverse events

KW - Bipolar disorder

KW - Cognition

KW - Treatment

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=85070550015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070550015&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2019.08.008

DO - 10.1016/j.jad.2019.08.008

M3 - Article

AN - SCOPUS:85070550015

VL - 261

SP - 277

EP - 281

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -